NeuroSense Therapeutics (NASDAQ:NRSN) Stock Price Down 0.9% – Here’s Why

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)’s stock price was down 0.9% during trading on Tuesday . The stock traded as low as $0.95 and last traded at $0.97. Approximately 56,197 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 239,378 shares. The stock had previously closed at $0.98.

NeuroSense Therapeutics Stock Down 0.9 %

The company’s fifty day simple moving average is $1.04 and its 200 day simple moving average is $1.10. The stock has a market capitalization of $13.26 million, a price-to-earnings ratio of -1.52 and a beta of 1.36.

NeuroSense Therapeutics (NASDAQ:NRSN) last posted its quarterly earnings data on Monday, April 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.12) by $0.06.

Institutional Inflows and Outflows

An institutional investor recently raised its position in NeuroSense Therapeutics stock. Citadel Advisors LLC lifted its holdings in shares of NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) by 640.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 253,997 shares of the company’s stock after purchasing an additional 219,717 shares during the quarter. Citadel Advisors LLC owned 1.86% of NeuroSense Therapeutics worth $305,000 as of its most recent SEC filing. Institutional investors and hedge funds own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.